{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:42:28Z","timestamp":1771807348272,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.intimp.2022.109381","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T12:13:16Z","timestamp":1666872796000},"page":"109381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"PA","title":["Association between AhR in B cells and systemic lupus erythematosus with renal damage"],"prefix":"10.1016","volume":"113","author":[{"given":"Liu","family":"Ting","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si","family":"Mingjun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cai","family":"Yuanyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Jingyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dian","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Li Juan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Haitao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.intimp.2022.109381_b0005","doi-asserted-by":"crossref","first-page":"ITC81","DOI":"10.7326\/AITC202006020","article-title":"Systemic Lupus Erythematosus [J]","volume":"172","author":"Kiriakidou","year":"2020","journal-title":"Ann. Intern. Med."},{"issue":"5","key":"10.1016\/j.intimp.2022.109381_b0010","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41584-020-0401-9","article-title":"Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy [J]","volume":"16","author":"Maria","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109381_b0015","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/art.39594","article-title":"Risk of end-stage renal disease in patients with Lupus Nephritis, 1971\u20132015 a systematic review and bayesian meta-analysis [J]","volume":"68","author":"Tektonidou","year":"2016","journal-title":"Arthritis Rheumatol."},{"issue":"10188","key":"10.1016\/j.intimp.2022.109381_b0020","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/S0140-6736(19)30237-5","article-title":"Management strategies and future directions for systemic lupus erythematosus in adults [J]","volume":"393","author":"Durcan","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"24","key":"10.1016\/j.intimp.2022.109381_b0025","doi-asserted-by":"crossref","first-page":"6231","DOI":"10.3390\/ijms20246231","article-title":"B cell abnormalities in systemic Lupus Erythematosus and Lupus Nephritis-role in pathogenesis and effect of immunosuppressive treatments [J]","volume":"20","author":"Yap","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2022.109381_b0030","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/j.ajkd.2019.10.017","article-title":"Update on Lupus Nephritis: core curriculum 2020 [J]","volume":"76","author":"Parikh","year":"2020","journal-title":"Am. J. Kidney Dis."},{"issue":"1","key":"10.1016\/j.intimp.2022.109381_b0035","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis [J]","volume":"6","author":"Anders","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"3","key":"10.1016\/j.intimp.2022.109381_b0040","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.it.2022.01.008","article-title":"Cell-intrinsic view of the aryl hydrocarbon receptor in tumor immunity [J]","volume":"43","author":"Dean","year":"2022","journal-title":"Trends Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2022.109381_b0045","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.3390\/ijms22084199","article-title":"Lipopolysaccharide-enhanced responses against aryl hydrocarbon receptor in FcgRIIb-deficient macrophages, a profound impact of an environmental toxin on a Lupus-like mouse model [J]","volume":"22","author":"Udompornpitak","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2022.109381_b0050","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.intimp.2019.01.039","article-title":"Association between the ratio of aryl hydrocarbon receptor (AhR) in Th17 cells to AhR in Treg cells and SLE skin lesions [J]","volume":"69","author":"Yu","year":"2019","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109381_b0055","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.cmet.2020.03.003","article-title":"Microbiota-derived metabolites suppress arthritis by amplifying aryl-hydrocarbon receptor activation in regulatory B cells [J]","volume":"31","author":"Rosser","year":"2020","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.intimp.2022.109381_b0060","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1084\/jem.20160789","article-title":"The aryl hydrocarbon receptor controls cell-fate decisions in B cells [J]","volume":"214","author":"Vaidyanathan","year":"2017","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2022.109381_b0065","doi-asserted-by":"crossref","first-page":"116","DOI":"10.15252\/embj.201695027","article-title":"Aryl hydrocarbon receptor is required for optimal B-cell proliferation [J]","volume":"36","author":"Villa","year":"2017","journal-title":"Embo. J."},{"key":"10.1016\/j.intimp.2022.109381_b0070","doi-asserted-by":"crossref","unstructured":"Hochberg M C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [J]. Arthritis Rheum, 1997, 40(9): 1725-.","DOI":"10.1002\/art.1780400928"},{"issue":"9","key":"10.1016\/j.intimp.2022.109381_b0075","doi-asserted-by":"crossref","first-page":"991-+","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus [J]","volume":"22","author":"He","year":"2016","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.intimp.2022.109381_b0080","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.1780350606","article-title":"A disease activity index for lupus patients. the committee on prognosis studies in SLE [J]","volume":"35","author":"Bombardier","year":"1992","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.intimp.2022.109381_b0085","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus [J]","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.intimp.2022.109381_b0090","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/0961203320979042","article-title":"Serum uric acid as a predictor for nephritis in Egyptian patients with systemic lupus erythematosus [J]","volume":"30","author":"Hafez","year":"2021","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.intimp.2022.109381_b0095","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10238-020-00657-w","article-title":"Evaluation of systemic lupus erythematosus disease activity using anti-\u03b1-enolase antibody and RDW [J]","volume":"21","author":"Huang","year":"2021","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2022.109381_b0100","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-021-02692-8","article-title":"Hematological malignancies in systemic lupus erythematosus: clinical characteristics, risk factors, and prognosis-a case-control study [J]","volume":"24","author":"Zhang","year":"2022","journal-title":"Arthritis Res. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2022.109381_b0105","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/acr.21902","article-title":"Significance of chronic tachycardia in systemic lupus erythematosus [J]","volume":"65","author":"Utset","year":"2013","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.intimp.2022.109381_b0110","first-page":"18","article-title":"Autoimmune conditions: systemic Lupus Erythematosus [J]","volume":"494","author":"Lam","year":"2020","journal-title":"FP Essent."},{"issue":"9","key":"10.1016\/j.intimp.2022.109381_b0115","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 european league against rheumatism\/american college of rheumatology classification criteria for systemic Lupus Erythematosus [J]","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol."},{"issue":"23","key":"10.1016\/j.intimp.2022.109381_b0120","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.3390\/ijms20236021","article-title":"Multiple functions of B cells in the pathogenesis of systemic Lupus Erythematosus [J]","volume":"20","author":"Ma","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2022.109381_b0125","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.celrep.2019.04.014","article-title":"Aryl hydrocarbon receptor interacting protein maintains germinal center B cells through suppression of BCL6 degradation [J]","volume":"27","author":"Sun","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.intimp.2022.109381_b0130","doi-asserted-by":"crossref","first-page":"109447","DOI":"10.1016\/j.cellsig.2019.109447","article-title":"TCDD-mediated suppression of na\u00efve human B cell IgM secretion involves aryl hydrocarbon receptor-mediated reduction in STAT3 serine 727 phosphorylation and is restored by interferon-\u03b3 [J]","volume":"65","author":"Blevins","year":"2020","journal-title":"Cell. Signal."},{"issue":"1","key":"10.1016\/j.intimp.2022.109381_b0135","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/toxsci\/kfy036","article-title":"Suppression of the IgM response by aryl hydrocarbon receptor activation in human primary B cells involves impairment of immunoglobulin secretory processes [J]","volume":"163","author":"Zhou","year":"2018","journal-title":"Toxicol. Sci.: Off. J. Soc. Toxicol."},{"key":"10.1016\/j.intimp.2022.109381_b0140","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1476-069X-9-15","article-title":"Disruption of human plasma cell differentiation by an environmental polycyclic aromatic hydrocarbon: a mechanistic immunotoxicological study [J]","volume":"9","author":"Allan","year":"2010","journal-title":"Environ. Health"},{"issue":"1","key":"10.1016\/j.intimp.2022.109381_b0145","doi-asserted-by":"crossref","first-page":"e000382","DOI":"10.1136\/lupus-2020-000382","article-title":"Neutrophil and lymphocyte counts are associated with different immunopathological mechanisms in systemic lupus erythematosus [J]","volume":"7","author":"Han","year":"2020","journal-title":"Lupus Sci. Med."},{"issue":"6","key":"10.1016\/j.intimp.2022.109381_b0150","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41590-018-0107-1","article-title":"Apoptotic cell-induced AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans [J]","volume":"19","author":"Shinde","year":"2018","journal-title":"Nat. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2022.109381_b0155","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/art.1780390716","article-title":"Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity [J]","volume":"39","author":"Manzi","year":"1996","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.intimp.2022.109381_b0160","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3892\/br.2015.544","article-title":"Dyslipidemia in patients with systemic lupus erythematosus: Association with disease activity and B-type natriuretic peptide levels [J]","volume":"4","author":"Yuan","year":"2016","journal-title":"Biomed. Rep."},{"issue":"4","key":"10.1016\/j.intimp.2022.109381_b0165","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.autrev.2015.12.007","article-title":"Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: a systematic review and meta-analysis of controlled trials [J]","volume":"15","author":"Sahebkar","year":"2016","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2022.109381_b0170","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-019-1482-z","article-title":"Urinary podocyte microparticles are associated with disease activity and renal injury in systemic lupus erythematosus [J]","volume":"20","author":"Lu","year":"2019","journal-title":"Bmc Nephrol."},{"issue":"11","key":"10.1016\/j.intimp.2022.109381_b0175","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1177\/0961203310371154","article-title":"The complex nature of serum C3 and C4 as biomarkers of lupus renal flare [J]","volume":"19","author":"Birmingham","year":"2010","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.intimp.2022.109381_b0180","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.kint.2017.11.010","article-title":"Aryl hydrocarbon receptor is activated in patients and mice with chronic kidney disease [J]","volume":"93","author":"Dou","year":"2018","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.intimp.2022.109381_b0185","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/imm.13418","article-title":"Haemoglobin drives inflammation and initiates antigen spread and nephritis in lupus [J]","volume":"165","author":"Sharma","year":"2022","journal-title":"Immunology"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922008657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922008657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:49:11Z","timestamp":1761587351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922008657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":37,"alternative-id":["S1567576922008657"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109381","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between AhR in B cells and systemic lupus erythematosus with renal damage","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109381","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109381"}}